<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603199</url>
  </required_header>
  <id_info>
    <org_study_id>GAS-460-11/12-1</org_study_id>
    <nct_id>NCT01603199</nct_id>
  </id_info>
  <brief_title>High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis</brief_title>
  <official_title>Impact of a High-protein High-fiber Diet on the Nutritional Status of Patients With Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary biliary cirrhosis is a chronic cholestatic autoimmune liver disease with a&#xD;
      progressive course that can lead to liver cirrhosis. There are few studies on dietary&#xD;
      management in primary biliary cirrhosis and most of them have focused on micronutrients&#xD;
      specifically vitamin D intake to prevent osteoporosis, and lipid control to prevent&#xD;
      hyperlipidemia, but few recommendations have been made regarding a complete dietary approach.&#xD;
      Fiber has been proven to increase the excretion of nitrogen products and consequently reduce&#xD;
      its blood levels, and an adequate protein intake (1- 1.5 g per kg) has shown to decrease&#xD;
      endogenous catabolism in cirrhotic patients.&#xD;
&#xD;
      The purpose of this study is to evaluate the impact of a high-protein, high-fiber diet in the&#xD;
      nutritional status of patients with primary biliary cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Participants will be followed for 6 months</time_frame>
    <description>Measured with the following parameters: body weight and height (to calculate BMI), triceps skinfold thickness and mid-arm circumference (to calculate mid-arm muscle circumference. Fat mass, fat free mass, total, intracellular and extracellular body water obtained by bioelectrical impedance analysis, and individual vectors obtained by bioelectrical impedance vector analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal hepatic encephalopathy</measure>
    <time_frame>Participants will be followed for 6 months</time_frame>
    <description>Assessed by Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Participants will be followed for 6 months</time_frame>
    <description>Assessed by SF-36 and PBC-40 questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Primary biliary cirrhosis (Non-cirrhotic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary biliary cirrhosis (Cirrhotic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High protein high fiber diet</intervention_name>
    <description>A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.</description>
    <arm_group_label>Primary biliary cirrhosis (Cirrhotic)</arm_group_label>
    <arm_group_label>Primary biliary cirrhosis (Non-cirrhotic)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Controls&#xD;
&#xD;
        Diagnose of primary biliary cirrhosis:&#xD;
&#xD;
          -  Biochemical evidence of cholestasis: based mainly on alkaline phosphatase elevation&#xD;
&#xD;
          -  Presence of antimitochondrial antibodies (AMA)&#xD;
&#xD;
          -  Histologic evidence of nonsuppurative destructive cholangitis and destruction of&#xD;
             interlobular bile ducts.&#xD;
&#xD;
        Ambulatory patients&#xD;
&#xD;
          -  Cases&#xD;
&#xD;
        Diagnose of primary biliary cirrhosis:&#xD;
&#xD;
          -  Biochemical evidence of cholestasis: based mainly on alkaline phosphatase elevation&#xD;
&#xD;
          -  Presence of antimitochondrial antibodies (AMA)&#xD;
&#xD;
          -  Histologic evidence of nonsuppurative destructive cholangitis and destruction of&#xD;
             interlobular bile ducts.&#xD;
&#xD;
        Diagnose of liver cirrhosis by two or more of the following criteria:&#xD;
&#xD;
          -  Albumin &lt; 3.4 g/dL&#xD;
&#xD;
          -  INR ≥ 1.3&#xD;
&#xD;
          -  Total bilirubin ≥ 2 mg/dL&#xD;
&#xD;
          -  Portal hypertension (esophageal varices, splenomegaly, ascites, etc.)&#xD;
&#xD;
          -  Liver biopsy Ambulatory patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Overlapping syndrome with predominant autoimmune hepatitis&#xD;
&#xD;
          -  Hospitalized patients&#xD;
&#xD;
          -  Acute or chronic renal failure&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Neuropsychiatric disorders (Schizophrenia, bipolar disorder, dementia and&#xD;
             attention-deficit hyperactivity disorder)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Torre Delgadillo, M.D. M.Sc</last_name>
    <role>Study Chair</role>
    <affiliation>INCMNSZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2012</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

